Call us for Counseling - 9580048004, For Support - 8860807050.  

Tags Current Affairs

Sputnik V effectiveness

Date: 14 April 2021 Tags: Miscellaneous


Sputnik V has been given for emergency use authorisation by the Drugs Controller General of India. It will be the third vaccine to get approval.



The Sputnik V vaccine is developed by the Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow.



  • The vaccine makes use of two types of virus causing common cold in humans. These adenovirus are weakened to prevent them from causing serious disease.

  • It will also deliver the code for making coronavirus spike protein in body. When the real virus is encountered, the body is able to provide anti-body response.

  • The vaccine uses two different vectors in two different vaccine shots. This will ensure that immunity remains for a longer duration in comparison of using the same vector in both shots.

  • Sputnik V is stored in-18°C in its liquid form. The two vaccine shots have to be given 21 days apart. It costs less than $10 for each shot.



  • The vaccine had come under criticism from scientific community after it was launched without complete studies.

  • The Phase 3 studies have indicated that its efficacy is about 91%. Dr Reddy’s has conducted a bridging study in India.

Notice (8): Undefined variable: quizpole [ROOT/plugins/Studyiq/src/Template/Pages/tagdetails.ctp, line 161]